Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 2/20 | 0.36 |
| ▸ | ADH1C | P00326 | 2/20 | 0.36 |
| ▸ | ADH1A | P07327 | 2/20 | 0.36 |
| ▸ | ADH4 | P08319 | 1/20 | 0.36 |
| ▸ | TLR4 | O00206 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | GSR | P00390 | 1/20 | 0.32 |
| ▸ | ADH7 | P40394 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17305116 | 1.00 | ADH1B (0.36) | ADH1BADH1CADH1AADH4TLR4 | |
| SCHEMBL1322225 | 1.00 | ADH1B (0.36) | ADH1BADH1CADH1AADH4TLR4 | |
| SCHEMBL14916899 | 0.98 | ADH1B (0.33) | ADH1BADH1CADH1AADH4TLR4 | |
| SCHEMBL14916898 | 0.98 | ADH1B (0.33) | ADH1BADH1CADH1AADH4TLR4 | |
| SCHEMBL8201986 | 0.93 | — | — | |
| SCHEMBL6978118 | 0.87 | — | — | |
| SCHEMBL6978120 | 0.87 | — | — | |
| SCHEMBL16603009 | 0.77 | MITF (0.35) | — | |
| SCHEMBL16032970 | 0.76 | — | — | |
| SCHEMBL16032969 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110627725-B | 4-substituted 5-difluoromethyl-3-nitro-1H-pyrazole compound and preparation method and application thereof | 遵义医科大学 | 2022-10-18 | — | — | CN | disclosed |
| US-11174278-B2 | Functionalized phosphonates via Michael addition | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) | 2021-11-16 | — | — | US | disclosed |
| CN-112409408-A | Chiral phosphorus sulfur compound and Michael addition method thereof | 深圳湾实验室坪山生物医药研发转化中心 | 2021-02-26 | — | — | CN | disclosed |
| US-20200031855-A1 | FUNCTIONALIZED PHOSPHONATES VIA MICHAEL ADDITION | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2020-01-30 | — | — | US | disclosed |
| CN-110627725-A | 4-substituted 5-difluoromethyl-3-nitro-1H-pyrazole compound and preparation method and application thereof | 遵义医科大学 | 2019-12-31 | — | — | CN | disclosed |
| US-10435423-B2 | Functionalized phosphonates via Michael addition | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) | 2019-10-08 | — | — | US | disclosed |
| EP-2970215-B1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2019-04-17 | — | — | EP | disclosed |
| US-9969739-B2 | Tricyclic chiral compounds and their use in asymmetric catalysis | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2018-05-15 | — | — | US | disclosed |
| US-20180051044-A1 | FUNCTIONALIZED PHOSPHONATES VIA MICHAEL ADDITION | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2018-02-22 | — | — | US | disclosed |
| US-20170240512-A1 | HETEROCYCLE AND CARBOCYCLE DERIVATIVES HAVING TRKA INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-08-24 | — | — | US | disclosed |
| US-7332622-B2 | Process for preparing optically active nitro compounds and cyano compounds | KANTO KAGUKU KABUSHIKI KAISHA (JP) | 2008-02-19 | — | — | US | disclosed |
| US-7332622-B2 | Process for preparing optically active nitro compounds and cyano compounds | KANTO KAGUKU KABUSHIKI KAISHA (JP) | 2008-02-19 | — | — | US | disclosed |
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2007041061-A2 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| US-7169777-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-7160886-B2 | Acylated piperazine derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160886-B2 | Acylated piperazine derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-20040116699-A1 | Melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-06-17 | — | — | US | disclosed |
| EP-1358163-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002059095-A1 | MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031855-A1 | FUNCTIONALIZED PHOSPHONATES VIA MICHAEL ADDITION | PHOSPHO1, PTMS, PSPH | ADH1B 3625/4885ADH1C 3741/4885ADH1A 2634/4885 |
| US-20180051044-A1 | FUNCTIONALIZED PHOSPHONATES VIA MICHAEL ADDITION | PHOSPHO1, PTMS, PSPH | ADH1B 3625/4885ADH1C 3741/4885ADH1A 2634/4885 |
| US-20170240512-A1 | HETEROCYCLE AND CARBOCYCLE DERIVATIVES HAVING TRKA INHIBITORY ACTIVITY | NR5A2, NPY5R, MC5R | ADH1B 2593/4885ADH1C 3149/4885ADH1A 3508/4885 |
| US-10435423-B2 | Functionalized phosphonates via Michael addition | PHOSPHO1, PTMS, PSPH | ADH1B 3625/4885ADH1C 3741/4885ADH1A 2634/4885 |
| US-11174278-B2 | Functionalized phosphonates via Michael addition | PHOSPHO1, PTMS, PSPH | ADH1B 3625/4885ADH1C 3741/4885ADH1A 2634/4885 |
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | CYSLTR2, PTGER2, CYSLTR1 | ADH1B 1736/4885ADH1C 2053/4885ADH1A 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.